Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Dispatch

Candida spp. with Acquired Echinocandin Resistance, France, 2004–20101

Eric Dannaoui2, Marie Desnos-Ollivier2, Dea Garcia-Hermoso, Fredéric Grenouillet, Sophie Cassaing, Marie-Thérèse Baixench, Stéphane Bretagne, Françoise Dromer, Olivier LortholaryComments to Author , and the French Mycoses Study Group
Author affiliations: Institut Pasteur, Paris, France (E. Dannaoui, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, F. Dromer, O. Lortholary); Centre Hospitalier Universitaire de Besançon, Besançon France (F. Grenouillet); Centre Hospitalier Universitaire de Toulouse–Hôpital Rangueil, Toulouse, France (S. Cassaing); Hôpital Cochin, Paris (M.-T. Baixench)

Main Article

Table 2

In vitro susceptibility and Fksp mutations of 20 echinocandin-resistant Candida spp. isolates, France, 2004–2010

Patient no.
 Strain
 Species
 MIC, µg/m, AM3/RPMI 1640 medium
Fksp mutation
Caspofungin
 Micafungin
 Anidulafungin
 Gene
 Mutation
1* 05BL1-38 C. albicans 1/2 0.25/1 0.06/0.125 FKS1 (HS1) F641S
2* ODL13-1254 C. albicans 1/2 1/1 0.5/0.5 FKS1 (HS1) S645Y
3† 06BL2-127 C. albicans 2/2 1/0.5 0.125/0.125 FKS1 (HS1) F641S‡ + S645P‡
4 ODL19-1894 C. albicans 4/2 2/2 0.125/0.25 FKS1 (HS1) S645P
5* 08BL1-94 C. albicans 2/4 0.25/1 0.06/0.5 FKS1 (HS2) R1361G§
6* 08BL2-143 C. albicans 8/4 4/2 0.25/0.5 FKS1 (HS1) S645P
7* 09BL1-43 C. albicans 1/2 0.25/1 0.06/0.25 FKS1 (HS1) F641S
8* 09BL1-77 C. albicans 0.5/0.5 0.5/0.25 0.015/0.03 FKS1 (HS1) R647G§
9 06BL1-34 C. krusei 4/8 2/4 1/2 FKS1 (HS1) L648W§,¶
10* 10BL1-50 C. krusei 2/4 1/2 0.06/1 FKS1 (HS1) F645L§,¶
11 ODL7-647 C. glabrata 8/8 0.5/1 0.25/0.125 FKS2 DelF658#
12* 07BL2-157 C. glabrata 4/1 1/0.5 0.25/0.5 FKS2 DelF658#
13* 06BL1-33 C. glabrata 8/8 4/8 2/2 FKS2 S663P
14* ODL21-2028 C. glabrata 1/1 0.25/0.25 0.25/0.25 FKS1 S629P
15* ODL22-2183 C. glabrata 8/2 0.25/0.25 0.25/1 FKS2 S663P
16 ODL23-2221 C. glabrata 1/4 0.06/2 0.06/0.25 FKS1 + FKS2 F625I§ (FKS1) + P667T§ (FKS2)
17* 08BL2-142 C. glabrata 1/4 0.25/2 0.25/2 FKS2 S663P
18 09BL1-55 C. glabrata 8/4 2/4 0.5/0.5 FKS2 S663P
19 10BL1-19 C. glabrata 0.5/4 0.06/0.5 0.06/1 FKS2 F659S + L664V§
20 10BL1-67 C. glabrata 4/4 0.5/1 0.125/1 FKS2 DelF658#

*Parentage of initial isolate available.
†In this patient, another isolate with reduced susceptibility to echinocandin was retrieved. This isolate harbored an S645P mutation in FKS1.
‡Heterozygous mutation.
§Mutations not already described (13).
¶Strains had also an L701M mutation.
#Deletion.

Main Article

References
  1. Pappas  PG, Kauffman  CA, Andes  D, Benjamin  DK Jr, Calandra  TF, Edwards  JE Jr, Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. DOIPubMedGoogle Scholar
  2. Baixench  MT, Aoun  N, Desnos-Ollivier  M, Garcia-Hermoso  D, Bretagne  S, Ramires  S, Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother. 2007;59:1076–83. DOIPubMedGoogle Scholar
  3. Pfeiffer  CD, Garcia-Effron  G, Zaas  AK, Perfect  JR, Perlin  DS, Alexander  BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010;48:2373–80. DOIPubMedGoogle Scholar
  4. Sun  HY, Singh  N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents. 2010;35:211–8. DOIPubMedGoogle Scholar
  5. Perlin  DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121–30. DOIPubMedGoogle Scholar
  6. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing. (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth microdilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect. 2008;14:398–405. DOIPubMedGoogle Scholar
  7. Desnos-Ollivier  M, Bretagne  S, Raoux  D, Hoinard  D, Dromer  F, Dannaoui  E. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother. 2008;52:3092–8. DOIPubMedGoogle Scholar
  8. Katiyar  S, Pfaller  M, Edlind  T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:2892–4. DOIPubMedGoogle Scholar
  9. Foulet  F, Nicolas  N, Eloy  O, Botterel  F, Gantier  JC, Costa  JM, Microsatellite marker analysis as a typing system for Candida glabrata. J Clin Microbiol. 2005;43:4574–9. DOIPubMedGoogle Scholar
  10. Garcia-Hermoso  D, Cabaret  O, Lecellier  G, Desnos-Ollivier  M, Hoinard  D, Raoux  D, Comparison of microsatellite length polymorphism and multilocus sequence typing for DNA-based typing of Candida albicans. J Clin Microbiol. 2007;45:3958–63. DOIPubMedGoogle Scholar
  11. Garcia-Hermoso  D, MacCallum  DM, Lott  TJ, Sampaio  P, Serna  MJ, Grenouillet  F, Multicenter collaborative study for standardization of Candida albicans genotyping using a polymorphic microsatellite marker. J Clin Microbiol. 2010;48:2578–81. DOIPubMedGoogle Scholar
  12. Arendrup  MC, Park  S, Rodriguez-Tudela  JL, Hope  W, Lass-Flörl  C, Donnelly  PJ, EUCAST susceptibility testing of Candida species to echinocandins: improved separation between wild type isolates and fks mutants by supplementation of BSA to the test medium. 21st European Congress of Clinical Microbiology and Infectious Diseases 27th International Congress of Chemotherapy; 2011; Milan, Italy.
  13. Pfaller  MA, Diekema  DJ, Andes  D, Arendrup  MC, Brown  SD, Lockhart  SR, Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat. 2011;14:164–76. DOIPubMedGoogle Scholar
  14. Lortholary  O, Desnos-Ollivier  M, Sitbon  K, Fontanet  A, Bretagne  S, Dromer  F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55:532–8. DOIPubMedGoogle Scholar
  15. Blanchard  E, Lortholary  O, Boukris-Sitbon  K, Desnos-Ollivier  M, Dromer  F, Guillemot  D, Prior caspofungin exposure in patients with haematological malignancies is a risk factor for subsequent fungemia due to decreased susceptible Candidda spp.: a case-control study in Paris, France. Antimicrob Agents Chemother. 2011;55:5358–61. DOIPubMedGoogle Scholar

Main Article

1This work was presented in part at the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10–13, 2010 (abstract no. O346).

2These authors contributed equally to this article.

3Additional members of the French Mycoses Study Group who contributed data are listed at the end of this article.

Page created: December 19, 2011
Page updated: December 19, 2011
Page reviewed: December 19, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external